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Article
Management of desmoid-type fibromatosis 
involving peripheral nerves
Tratamento da fibromatose tipo desmoide envolvendo nervos periféricos
Mario G. Siqueira1, Paulo L. Tavares1, Roberto S. Martins1, Carlos O. Heise1, Luciano H.L. Foroni1, Marcelo 
Bordalo2, Roberto Falzoni3
Desmoid-type fibromatosis (DTF) is a fibrous prolifera-
tion from fascia and musculoaponeurotic tissues localized 
mainly in the abdomen. Owing to its slow growing and no 
risk of metastatization, these rare neoplastic lesions are re-
garded as benign, but the tendency of local invasion and the 
high rate of recurrence leads to significant morbidity by de-
struction of adjacent vital structures. There is no consensus 
about the best modality of treatment for these lesions, that 
ranges from wait-and-see and clinical treatment to radical 
surgery and radiotherapy. Due to the rarity of these tumors, 
evidence regarding the best treatment protocol for each case 
is drawn from case reports and small series of patients in the 
literature. The lesions involving or compressing peripheral 
nerves are even rarer and its ideal management has not been 
defined. In this report, we present four cases of desmoid-type 
fibromatosis involving the peripheral nerve. The different 
ways to manage these lesions are critically analyzed, and an 
attempt to define therapeutic suggestions is made.  
cASe rePOrt 
case 1 
Male, 22-years-old, with a slow growing mass in the medi-
al region of the right arm, immediately proximal to the medial 
epicondyle of the humerus, for seven years. In 1998, he was sub-
mitted to surgical treatment in another institution. The resec-
tion was reported as complete and the histological diagnosis 
was neurofibroma. In 2002, the tumor recurred and the same 
surgeon resected a 12 centimeters mass with firm adhesions 
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ABStrAct
Desmoid-type fibromatosis is an uncommon and aggressive neoplasia, associated with a high rate of recurrence. It is characterized by an 
infiltrative but benign fibroblastic proliferation occurring within the deep soft tissues. There is no consensus about the treatment of those tu-
mors. We present a surgical series of four cases, involving the brachial plexus (two cases), the median nerve and the medial brachial cutane-
ous nerve. Except for the last case, they were submitted to multiple surgical procedures and showed repeated recurrences. The diagnosis, the 
different ways of treatment and the prognosis of these tumoral lesions are discussed. Our results support the indication of radical surgery 
followed by radiotherapy as probably one of the best ways to treat those controversial lesions. 
Key words: desmoid-type fibromatosis, desmoid tumor, fibromatosis, peripheral nerve.
reSUMO
A fibromatose do tipo desmoide é uma lesão tumoral agressiva e rara, associada a alto índice de recorrência. É caracterizada pela fibroblás-
tica infiltrativa, porém benigna, que ocorre no interior de tecidos moles profundos. Não existe consenso com relação ao tratamento desses 
tumores. Apresentamos uma série cirúrgica de quatro casos comprometendo o plexo braquial (dois casos), o nervo mediano e o nervo cutâ-
neo medial do braço. Com exceção do último caso, todos foram submetidos a múltiplos procedimentos cirúrgicos e apresentaram recorrên-
cias repetidas. São discutidos o diagnóstico, as diferentes formas de tratamento e o prognóstico dessas lesões tumorais. Nossos resultados 
apoiam o conceito de que cirurgia radical seguida por radioterapia é uma das melhores formas de se tratar essas controvertidas lesões.
Palavras-Chave: fibromatose tipo desmoide, tumor desmoide, fibroma, nervos periféricos.  
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to the periosteum of the humerus and to other deep tissues, 
including the median and ulnar nerves. Once again, the histo-
logical diagnosis was of a neurofibroma. In 2004, a new recur-
rence, provoking local pain with irradiation to the distal ulnar 
nerve distribution, brought the patient to our institution. At 
examination, we observed two firm masses, one immediately 
proximal to the elbow and the other about 5 centimeters prox-
imal and apart to the first one, both in the medial surface of 
the right arm (Fig 1). There were no neurological deficits. Two 
hardened masses with 10 and 11 centimeters in their largest 
diameters, with great adhesion to the adjacent muscles and 
apparent invasion in some areas, were founded at surgery. The 
ulnar nerve was dislocated inferior and medially, and the me-
dian nerve and the brachial artery were inside the proximal tu-
mor. The resection was apparently complete and no additional 
neurological deficits were observed. The pain disappeared in 
the immediate postoperative period. The histological diagnosis 
now was of DTF. The patient refused any adjuvant treatment 
and one year after the last surgery a new lesion developed at 
the proximal limit of the surgical scar, without neurological im-
pairment. Two solid masses, with 4 centimeters each in their 
largest diameters, extending to the axillary region, involving 
and compressing the median and ulnar nerves, were resect-
ed in the proximal arm. The limit of the lesions with the adja-
cent fibrosis and muscles was totally imprecise in some areas. 
After histological confirmation of recurrent DTF, the patient 
was submitted to complementary treatment with radiother-
apy. After two years, the tumor recurred outside the radiation 
field, now in the infraclavicular area, and was removed once 
again. Since this last surgery, performed two years ago, the pa-
tient is doing well.
case 2
Female, 33-years-old, had a previous resection of a left 
subcutaneous axillary nodule in another institution. We 
have no description of the procedure or of the mass histopa-
thology. Fourteen months later, she was referred to us with 
a new axillary nodule, at the same site, complaining of pain, 
hypoesthesia and paresthesias in the medial aspect of the 
arm (medial brachial cutaneous nerve territory) and show-
ing a tingling sensation evoked by percussion of the nodule. 
MRI demonstrated a nodular mass (12x8x7 mm) in the left 
axilla, well circumscribed, related to nervous structures, 
but without infiltrative characteristics. Intraoperatively, the 
nodule was involved by fibrous tissue, probably related to 
the previous procedure, and was compressing the medial 
brachial cutaneous nerve. The nerve was anatomically in-
tact under the lesion. Total surgical removal was performed 
and, surprisingly, the histopathological diagnosis was DTF. 
The pain resolved and the patient is recovering her sensi-
tive deficit. The patient is well, without recurrences, sixteen 
months after surgery.  
case 3 
Female, 34-years-old, was submitted to resection of a right 
supraclavicular mass two years before in another institution, 
with a diagnosis of DTF. One year later, she had a recurrence 
in the same place, without associated neurological deficits or 
A
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Fig 1. Case 1. (A) Two masses in the medial surface of the right arm (arrows), one immediately proximal to the elbow and the other 
about 5 cm proximal and apart to the first one. (B) Coronal T2-weighted MR image, with fat-supression, showing two masses 
with high signal intensity with areas of low signal intensity inside (possible fibrosis), localized in the proximal and distal thirds of 
the arm. Brachial artery (arrow); T: tumor. (C) Intraoperative photograph showing the distal tumor (T) dislocating the ulnar nerve 
(U) and involving the median nerve (not shown). (D) Intraoperative photograph after removal of the tumor. Brachial artery (arrow); 
medial antebrachial cutaneous nerve (double arrow); M: median nerve; U: ulnar nerve. 
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pain. The tumor was partially resected and the patient was re-
ferred to our hospital. On the first examination, the patient 
was neurologically intact and a voluminous mass was ob-
served in her right supraclavicular region. Paresthesias were 
elicited by manipulation of the mass. The MRI showed a large 
lobulated mass (8.5x8.0x5.0 cm) compressing the anterior sca-
lenus muscle and infiltrating the multifidus, levator scapulae 
and posterior scalenus muscles (Fig 2). The upper and middle 
trunks of the brachial plexus were involved, and the tumor dis-
located the lower trunk, as well as the proximal segments of 
the internal jugular and subclavian veins. Gadolinium intrave-
nous injection provoked a heterogeneous enhancement of the 
mass. A radical resection of the lesion was performed, with-
out compromising the neurological status of the patient, and 
DTF diagnosis was confirmed. The surgery was soon followed 
by radiotherapy. The patient is still doing well after five years of 
follow-up, with no evidences of recurrence. 
case 4
 Female, 19-years-old, had a right subscapular mass re-
moved in 2005 and a right neck mass resected in 2006 in anoth-
er institution. In both lesions the diagnosis of DTF was made. 
Five months later, the patient observed a growing mass in the 
area of the neck surgery. Except for mild local pain, the patient 
was asymptomatic. MRI demonstrated recurrence of both le-
sions, the subscapular measuring 6.5x4.0x2.0 cm and the cervi-
cal lesion with 9.0x7.0x3.0 cm. The posterior mass was located 
between the trapezius muscle and the right scapula. The right 
cervical lesion was medial to the sternocleidomastoid muscle 
and posterior to the internal jugular vein and carotid artery. The 
cervical mass was infiltrating the anterior and middle scalenus 
muscle and involved the C7 brachial plexus root and the phren-
ic nerve. Both lesions were radically resected, and, after the 
histological diagnosis of DTF, the patient was referred to 
the radiotherapy department. The patient is neurologically in-
tact almost four years after the last surgery and there is no evi-
dence of recurrence. 
DiScUSSiON
Over the years, many terms have been used to describe 
this tumor, including: desmoid tumor, well-differentiated 
nonmetastasizing fibrosarcoma, fibrosarcoma, Grade I fibro-
sarcoma, aggressive fibromatosis and desmoid-type fibroma-
tosis (DTF), the last term being the designation of choice of 
the World Health Organization1. DTFs typically evolve over 
a period of three years and stabilize thereafter. Recurrences 
or progression most commonly occurs between 14 and 17 
months after surgical resection2. It is estimated that these 
tumors account for 0.03% of all neoplasms and comprise 
around 3% of all soft tissue neoplasms3,4, with an annual oc-
currence of 2.4 to 4.5 new cases per million persons3, but the 
real incidence of DTF is difficult to ascertain, mainly because 
of the multiple denominations attributed to these lesions. 
In the largest published series of peripheral nerve tumors 
(Louisiana State University Health Sciences Center – 543 tu-
mors), these lesions comprised only 2.0% of the cases3,5. 
Macroscopically, DTF is a rubbery gray-whitish lesion with 
a scar appearance, without a capsule, that can reach large 
Fig 2. Case 3. (A) RM, Coronal T2-weighted MR image, with fat-supression, demonstrating a large mass with high signal intensity 
in the supraclavicular region, involving/dislocating the brachial plexus. (B). Intraoperative photograph demonstrating a large 
tumoral mass (T) in the supraclavicular region. Penrose drains identifying brachial plexus elements. C: clavicle. (C) Intraoperative 
photograph after removal of the tumor. C: clavicle. (D) Macroscopic aspect of the tumor removed.  
A
D
B
C
C
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dimensions (up to 20 cm). Its histology is characterized by a 
local infiltrative process composed by mature fibroblasts or 
myofibroblasts in an abundant collagen matrix, without any 
evidence of cellular anaplasia or abnormal mitoses (Fig 3). 
Although regarded as benign lesions, DTFs are locally infiltra-
tive. They usually invade the adjacent muscles and occasion-
ally penetrate the trabecular spaces of bones in the area. They 
can also invade, involve or compress nerves and vessels, as in 
the cases we are reporting, and sometimes can grow inside 
scars. The destruction of adjacent vital structures and organs 
can cause extensive morbidity. The more aggressive lesions are 
characterized by a larger number of myofibroblasts, while the 
less aggressive show a larger number of mastocites. There is no 
report of regional linfonode involvement6. 
First described in the abdominal wall of pregnant women, 
DTFs can occur virtually in any area of the body, but two thirds of 
these lesions are originated from the anterior aponeurosis of 
the rectus abdominis muscle2, and are frequently associated 
with the autosomal-dominant familial adenomatous polypo-
sis of the colon (Gardner syndrome). The majority of the extra-
abdominal DTFs, frequently called aggressive fibromatosis, is 
originated from muscles/aponeurosis in the shoulder and pel-
vic girdles, and are solitary and sporadic7. Multicentric tumors, 
like our case #4, are even more rare2. There are few reports of 
DTFs originated inside nerves, probably from stroma cells8. 
The DTFs resemble a fibrosarcoma for its infiltrative capacity, 
but they do not metastasize. These slow growing neoplasias, 
although with extremely rare occurrence of malignant degen-
eration, present a high incidence of recurrence, like in our cas-
es #1, 3 and 4, owing to its high propensity for local invasion9. 
The difficulty in performing an oncologic resection in most 
cases facilitates this high level of recurrence. Although the re-
section seems to be radical in many cases, the histological ex-
amination, as in our cases #1, 3 and 4, frequently demonstrates 
invasion of the adjacent tissues. The possible risk factors for re-
currence include patient age, gender, tumor size, location, sta-
tus of disease (primary or recurrent), surgical margins, limb/
girdle or intra-abdominal location, omission of radiotherapy, 
radiation dose less than 50 Gy and insufficient radiation field 
size (case #1).
The etiology of the DTFs is unknown, despite trauma and 
endocrinological factors had been frequently implicated in 
its pathogenesis10. The age and sex of our patients is in ac-
cordance with the literature, as the process tends to involve a 
younger population ( from puberty to 40 years) and to affect 
women more often. There is no ethnic prevalence.
The clinical presentation varies depending on the local-
ization of the lesion. Usually, the patients search for medical 
care because of a slow growing mass, sometimes painful, that 
may compromise adjacent nerve and vascular structures, as 
in our cases. 
Image evaluation of DTFs can be done by computed to-
mography (CT) or magnetic resonance imaging (MRI), the 
MRI being considered superior in evaluating the pattern of 
tumor growth, as well as the involvement of nearby struc-
tures. On CT scans, the lesion appears hyperattenuated with 
significant enhancement after contrast injection11. In MRI, 
the lesion appears hypointense to isointense relative to mus-
cle on T1-weighted imaging, and with a signal intensity simi-
lar to fat on T2-weighted images12.
There is no consensus regarding the best treatment DTFs. 
Since it is a heterogeneous disease, treatment should be in-
dividualized to achieve local tumor control with concurrent-
ly acceptable morbidity and preservation of quality of life. 
At present, the management of patients with these tumors 
usually includes surgery, radiation therapy and cytotoxic and 
noncytotoxic chemotherapy. 
All our patients were submitted to surgical resection, 
which is currently the mainstay treatment. When technically 
feasible, the ideal treatment would be an en bloc radical sur-
gical excision of the lesion, with negative microscopic margins, 
even if this approach carries the risk of some functional and/or 
cosmetic compromise. Owing to the difficulty for the surgeon to 
clearly delineate the margins of the lesion due to the infiltrative 
Fig 3. Photomicrograph of tissue from desmoid-type fibromatosis (Case 1), demonstrating: (A) Neoplastic proliferation of 
fibroblastic cells permeating skeletal muscle tissue and adipose tissue (100x HE); (B) Fibroblastic neoplastic cells in different 
stages of maturation, without atypias, necrosis or mitosis (400x HE). 
A B
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properties of the tumor, a margin of 2 to 3 cm beyond de edg-
es of palpable tumor to achieve local control is advocated3, but 
in some special locations, like in the brachial plexus region 
 (cases # 3 and 4), this oncological approach is not possible with-
out sacrificing important nerves and vessels7,13. The extension 
of the first resection seems to be the most important associ-
ated factor related to the level of recurrence14. Except for case 
#2, all the others were operated before admission in our institu-
tion and we had no reliable information about the extension of 
the first or second resection. In the subtotal surgical resections, 
with positive microscopic margins, the incidence of recurrence 
can reach levels of 90%15, but, even when resection with a wide 
surgical margin is achieved, the local recurrence rate remains 
high. Positive surgical margins after surgical resection are con-
troversial as risk factors for tumor recurrence16. The importance 
of evaluating the risk/benefit ratio of obtaining a more extensive 
tumor resection at the expense of putting neurovascular struc-
tures at risk should be emphasized.  
Despite its low mitotic index, DTFs have some radiosensitiv-
ity, and complementary treatment with radiotherapy (RT) has 
been used as the first treatment in patients who are not good 
surgical candidates17 and in some recurrence cases16. Although 
the results are quite variable, this type of treatment seems to 
lead to some local control18,19. The usual radiation doses (ap-
proximately 50 Gy) and the application of modern, conformal 
radiation treatment planning techniques for the minimization 
of normal tissue dose, keeps the risk of complications at a low 
level20. Having in mind that the patients are usually young and 
otherwise healthy, and considering the normal tissue toxicity 
and potential late radiation effects, some researchers claim that 
RT should be pursued only in patients with gross residual dis-
ease21. But, the higher incidence of recurrence in the cases that 
did not receive RT made some authors to change the approach 
and proceed with RT after the initial surgery22. Except for case 
#2, a small and circumscribed lesion, all our patients received 
postoperative radiotherapy. Taking into account the long post-
operative period without recurrence in cases #3 and #4, and the 
recurrence outside the radiation field in case #1, this modality of 
treatment was apparently beneficial to our patients.
There are several recent reports in the literature indicating 
for the possibility of adjuvant medical therapy with cytotoxic 
chemotherapeutic agents used for sarcomas (methotrexate, 
cyclophosphamide, ifosamide, etoposide, cisplatin, vinblastine 
and doxorubicin) and with hormonal (noncytotoxic) chemo-
therapy (tamoxifen, testolactone, medroxyprogesterone)23-25. 
Hormonal therapy has been tried based on the female pre-
dominance of the disease and the finding that some of these 
tumors exhibit estrogen receptors. The evidence regarding 
the efficacy of these agents is drawn from small number of 
patients. When using this type of drug, one must remember 
that the probability of complications is reasonable and that the 
possibility of remission or stabilization of the disease in 
the literature does not surpass 50%25. This type of therapy 
should be reserved for the unresectable and recurrent cases. 
A drug that deserves special mention is the imatinib mesy-
late, a recently developed oral anticancer agent designed to 
selectively inhibit tyrosine kinases implicated in oncogenesis. 
Although the precise target and predictive factors for response 
to treatment in patients with DTFs are unknown, it seems that 
imatinib is active in the treatment of recurrent and progressive 
lesions, providing objective response and long-term stable dis-
ease in a large proportion of patients26.
 There are also reports in the literature of the use of non-ste-
roid anti-inflammatory drugs, oral contraceptives, vitamin K, 
warfarin and vitamin C, isolated or combined, as adjuvant ther-
apy for these lesions27. Despite many of these therapies do not 
present definitive prove of its efficacy, they are frequently used 
in partially resected and recurrent lesions. 
Recently, new modalities of treatment of DTFs like intraop-
erative electron radiotherapy28, radiofrequency ablation29 and 
cryoablation30, have been reported. Although these treatments 
yielded good local control rates, their efficacy must be validated 
in a larger number of patients.
In summary, desmoid-type fibromatosis are neoplasms 
with an unpredictable biologic behavior, being difficult to af-
firm that they can be controlled. A treatment strategy should 
be idealized for each patient, however the analysis of our se-
ries and of the recent literature lead us to the conclusion that a 
radical surgical resection followed by radiation therapy seems 
to be the best protocol available at the moment. Long-term 
follow-up with imaging studies is always necessary to detect 
possible tumor recurrence. 
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